Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Cell and Gene Therapy Development
Thermo Fisher Scientific Inc., announced the grand opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company’s second ATxCC in the United States following the opening of its Carlsbad, California, site. Together, these centers expand the company’s nationwide network supporting cell and gene therapy (CGT) innovation, providing critical resources to biotech, biopharma and translational researchers developing next-generation cell-based immunotherapies.
Advanced therapies represent one of the most promising frontiers in modern medicine, offering the potential to treat, and even cure, diseases once considered untreatable. As demand for these therapies grows, so does the need for scalable, innovative solutions. The opening of Thermo Fisher’s new East Coast center highlights the company’s ongoing investment in enabling these breakthroughs and advancing the future of healthcare.
“Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing cell and gene therapies,” said Nicole Brockway, president, biosciences, Thermo Fisher Scientific. “This center will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster.”
Located within BioLabs for Advanced Therapeutics Philadelphia, a newly expanded 53,000-square-foot biotech incubator in the heart of the city, the Philadelphia ATxCC provides emerging startups and biopharma organizations with direct access to Thermo Fisher’s expert scientists, advanced process development technologies and collaboration opportunities.
"We’re proud to expand our network-wide partnership with Thermo Fisher Scientific through this unique offering. By embedding the ATxCC within the BioLabs community, we are creating a uniquely rich and accessible resource for founders and startup teams working on groundbreaking therapies in Philadelphia,” said Johannes Fruehauf, PhD, MD, Founder and CEO of BioLabs, the premier global network of life science incubators. “It will offer game-changing access to high-end technologies not only for our BioLabs members but also to external high-potential biotechs from across the East Coast and internationally.”
